ZA985129B - The use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for influencing the homocysteine level particularly for asissting the remethylation of homocysteine - Google Patents

The use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for influencing the homocysteine level particularly for asissting the remethylation of homocysteine

Info

Publication number
ZA985129B
ZA985129B ZA985129A ZA985129A ZA985129B ZA 985129 B ZA985129 B ZA 985129B ZA 985129 A ZA985129 A ZA 985129A ZA 985129 A ZA985129 A ZA 985129A ZA 985129 B ZA985129 B ZA 985129B
Authority
ZA
South Africa
Prior art keywords
homocysteine
tetrahydrofolates
remethylation
production
pharmaceutical preparation
Prior art date
Application number
ZA985129A
Other languages
English (en)
Inventor
Hans Rudolf Mueller
Martin Ulmann
Rudolf Moser
Original Assignee
Eprova Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4210897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA985129(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eprova Ag filed Critical Eprova Ag
Publication of ZA985129B publication Critical patent/ZA985129B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA985129A 1997-06-13 1998-06-12 The use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for influencing the homocysteine level particularly for asissting the remethylation of homocysteine ZA985129B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH01456/97A CH693255A5 (de) 1997-06-13 1997-06-13 Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.

Publications (1)

Publication Number Publication Date
ZA985129B true ZA985129B (en) 1998-12-14

Family

ID=4210897

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA985129A ZA985129B (en) 1997-06-13 1998-06-12 The use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for influencing the homocysteine level particularly for asissting the remethylation of homocysteine

Country Status (15)

Country Link
US (1) US6011040A (fr)
EP (2) EP0898965B9 (fr)
JP (1) JPH11116482A (fr)
CN (1) CN102151271A (fr)
AT (2) ATE538793T1 (fr)
AU (1) AU739544B2 (fr)
CA (1) CA2240571C (fr)
CH (1) CH693255A5 (fr)
DE (1) DE59813465D1 (fr)
DK (2) DK1685840T3 (fr)
ES (2) ES2376472T3 (fr)
PT (2) PT1685840E (fr)
RU (1) RU2226099C2 (fr)
TW (1) TW474812B (fr)
ZA (1) ZA985129B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69728379T2 (de) 1996-01-31 2005-02-24 South Alabama Medical Science Foundation, Mobile Lebensmittel und vitamin herstellungen mit natürlichem isomeren von reduzierten folaten
AU5547099A (en) * 1998-08-03 2000-02-28 Epigenesis Pharmaceuticals, Inc. A new analgesic, anti-inflammatory and wound healing agent
US20020094970A1 (en) * 2000-12-14 2002-07-18 Ronenn Roubenoff Compositions and methods for treating an arthritic condition
DE10062401A1 (de) * 2000-12-14 2002-06-20 Beiersdorf Ag Verwendung von Folsäure und/oder deren Derivaten zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Prophylaxe von Schäden an der hauteigenen DNA und/oder zur Reparatur bereits eingetretener Schäden an der hauteigenen DNA
FR2828076B1 (fr) * 2001-07-31 2003-11-07 Olivier Laroche Banquette pour musicien
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
SE0303526D0 (sv) 2003-12-22 2003-12-22 Biofol Ab Chemotherapeutic agents
DK1708690T3 (en) 2003-11-17 2016-11-07 Biomarin Pharm Inc TREATMENT OF PHENYLKETONURI WITH BH4
US8003126B2 (en) * 2004-11-17 2011-08-23 Biomarin Pharmaceutical Inc. Stable tablet formulation
AU2005313940A1 (en) * 2004-12-08 2006-06-15 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2006074416A1 (fr) * 2005-01-07 2006-07-13 Health Research Inc. 5-amino-4-imidazolecarboxamide riboside et sa nucléobase en tant qu'agents amplificateurs du transport et du métabolisme d'antifolates
WO2006119589A2 (fr) * 2005-05-11 2006-11-16 Ramaekers, Vincent Prevention et traitement de la carence en folates cerebraux
DE102005023301B4 (de) * 2005-05-13 2012-05-31 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
US20060293295A1 (en) * 2005-05-13 2006-12-28 Kai Strothmann Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate
AU2012227235B2 (en) * 2005-05-13 2015-06-11 Bayer Intellectual Property Gmbh Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6S)-tetrahydrofolate
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
DE112007001600A5 (de) * 2006-07-06 2009-04-30 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) * 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
US20080064702A1 (en) * 2006-09-08 2008-03-13 Charalambos Antoniades Use of folates for the prevention and treatment of vascular diseases
DK2139485T3 (da) 2007-04-11 2013-01-21 Biomarin Pharm Inc Fremgangsmåder til admistration af tetrahydrobiopterin, associerede sammensætninger, og fremgangsmåder til måling
EP2027855A1 (fr) 2007-08-24 2009-02-25 Bayer Schering Pharma AG Utilisation de gestagènes conjointement à du (6S)5-méthyltetrahydrofolate pour le traitement de l'endométriose avec une diminution simultanée des effets secondaires du traitement tout comme diminution du risque de malformations congénitale lors de l'introduction d'une gravidité
US20090060997A1 (en) * 2007-08-27 2009-03-05 Christian Seitz Process for producing a pharmaceutical preparation for therapeutic treatment of endometriosis containing a combination of a gestagen and (6s)-5-methyltetrahydrofolate
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
CA2714340A1 (fr) * 2008-02-13 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Systeme d'administration de medicament contenant de l'estradiol
US20110171134A1 (en) * 2008-06-25 2011-07-14 Iskandar Bermans J (6s)-5-methyltetrahydrofolic acid for therapy of tissue injury
AU2010271178B2 (en) 2009-07-10 2015-10-22 Linzy O. Scott Iii Methods and compositions for treating thyroid-related medical conditions with reduced folates
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
EP3949973A3 (fr) 2010-02-12 2022-07-06 Gentelon, Inc. Compositions et procédés pour le traitement de la dépression
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US20160053281A1 (en) 2013-08-15 2016-02-25 The University Court Of The University Of Edinburgh Enhanced Expression Of RNA Vectors
WO2016185413A1 (fr) 2015-05-20 2016-11-24 Nestec S.A. Formulations à libération modifiée
AU2017397463B2 (en) 2016-11-03 2022-01-06 HedoniaUSA, Inc. Compositions and methods for treating depression
WO2018178144A1 (fr) * 2017-03-31 2018-10-04 Merck Patent Gmbh Sel de sodium cristallin d'acide 5-méthyl-(6s)-tétrahydrofolique
JP7285785B2 (ja) * 2017-03-31 2023-06-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ５－メチル－（６ｓ）－テトラヒドロ葉酸の結晶性ナトリウム塩

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1350160A (en) * 1971-06-29 1974-04-18 Foremost Mckesson Pharmaceutical compositions
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
ATE139799T1 (de) * 1989-12-11 1996-07-15 American Cyanamid Co Verfahren zur herstellung von optisch reinen diastereoisomeren von tetrahydrofolatverbindungen
WO1991017660A1 (fr) * 1990-05-11 1991-11-28 Spears Colin P 5,10-methylene-tetrahydrofolate comme modulateur d'un agent chimiotherapeutique
CH682664A5 (en) * 1991-10-15 1993-10-29 Eprova Ag Stable salts of 5,10-methylene tetrahydrofolate.
CH684644A5 (de) * 1992-07-13 1994-11-15 Eprova Ag 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.
JPH06192105A (ja) * 1992-09-14 1994-07-12 Vesta Medicines Pty Ltd ホモシステインのレベルを下げるための医薬製剤
CH689831A5 (de) * 1995-11-07 1999-12-15 Eprova Ag Stabile kristalline Tetrahydrofolsaeure-Salze.
DE69728379T2 (de) * 1996-01-31 2005-02-24 South Alabama Medical Science Foundation, Mobile Lebensmittel und vitamin herstellungen mit natürlichem isomeren von reduzierten folaten
US6008221A (en) * 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid

Also Published As

Publication number Publication date
US6011040A (en) 2000-01-04
ES2376472T3 (es) 2012-03-14
RU2226099C2 (ru) 2004-03-27
CN102151271A (zh) 2011-08-17
AU739544B2 (en) 2001-10-18
DK1685840T3 (da) 2012-04-10
CA2240571A1 (fr) 1998-12-13
ATE538793T1 (de) 2012-01-15
TW474812B (en) 2002-02-01
EP0898965A2 (fr) 1999-03-03
EP0898965A3 (fr) 2000-11-15
EP0898965B9 (fr) 2006-08-09
ATE321555T1 (de) 2006-04-15
CA2240571C (fr) 2006-08-08
DK0898965T3 (da) 2006-07-31
ES2262202T3 (es) 2006-11-16
EP1685840A3 (fr) 2010-06-02
EP1685840B1 (fr) 2011-12-28
PT898965E (pt) 2006-08-31
CH693255A5 (de) 2003-05-15
PT1685840E (pt) 2012-02-09
DE59813465D1 (de) 2006-05-18
AU7007998A (en) 1998-12-17
EP1685840A2 (fr) 2006-08-02
EP0898965B1 (fr) 2006-03-29
JPH11116482A (ja) 1999-04-27

Similar Documents

Publication Publication Date Title
ZA985129B (en) The use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for influencing the homocysteine level particularly for asissting the remethylation of homocysteine
Miller The effect of fluoride on higher plants with special emphasis on early physiological and biochemical disorders
WO2002058684A3 (fr) Combinaisons de medicaments (par exemple de chlorpromazine et de pentamidine) pour le traitement de troubles neoplasiques
HU9600657D0 (en) K-252a derivatives which enhance neurotrophin-induced activity
Siniscalchi et al. Increase in plasma homocysteine levels induced by drug treatments in neurologic patients
AU4830097A (en) Use of an extract of Cimicifuga
IL148963A0 (en) Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts of ginkgo biloba
WO2005025502A3 (fr) Procede permettant de traiter ou d'inhiber les effets de blessures ou maladies ayant pour consequence la degenerescence neuronale
WO2004108069A3 (fr) Compositions et methodes visant a favoriser l'excroissance neuronale
EP1105145A4 (fr) Procede et composition pharmaceutique destines a reduire la concentration plasmatique d'homocysteine
Rubin Art therapy: What it is and what it is not.
UA35566C2 (uk) Лікарський засіб для профілактики і лікування порушень ліпоїдного і холестеринового обміну речовин і спосіб профілактики і лікування цих порушень
NO984572D0 (no) Anvendelse av 2,5-dihydroksybenzensulfonderivater for fremstilling av legemidler ment for normalisering av den endoteliale funksjon, for behandling av seksuell dysfunksjon og vaskulµre komplikasjoner i diabetes, sÕvel som vaskulµre lidelser av e
Kral et al. Relationship of vitamin B12 and folic acid to memory function.
ATE286402T1 (de) Verwendung von morinda citrifolia zur behandlung von tinnitus
WO2000056295A3 (fr) Preparations administrables par voie orale associant l'hydroxocobalamine a l'acide folique
ZA972599B (en) Use of bradykinin antagonists for the production of pharmaceuticals for the treatment of chronic fibrogenetic liver disorders and acute liver disorders.
WO2002085341A3 (fr) Composition pour la prevention ou le traitement de troubles d'apprentissage chez les enfants souffrant de trouble d'hyperactivite avec deficit de l'attention
Menon et al. Sertraline and liver toxicity in the elderly.
EP0745597A3 (fr) Indanylpipérazines ou homopipérazines mélatonergiques
WO2001037832A3 (fr) Association de riluzole et de gabapentine et son utilisation comme medicament
Schaffer et al. Barrett's syndrome presenting as globus hystericus.
AU624739B2 (en) 3-substituted-2-oxindole derivatives as inhibitors of interleukin-1 biosynthesis
Arnold Experimental psychology and the deaf child.
WO2001043757A3 (fr) Composition contenant des ingredients de panax ginseng et de ginkgo biloba